Developer docs
API playgroundTry for free, no card

Search company profiles

Optellum

Full company profile

uuid0000gud

Namestring
Optellum
Legal namestring
Optellum Ltd.
Websiteurl
optellum.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Optellum is an Oxford-headquartered medtech company, founded in 2016 as a spinout from the University of Oxford, that develops AI-powered software for early lung cancer detection and lung nodule management. Its core platform, the Virtual Nodule Clinic (VNC), combines three proprietary technologies: Lung Cancer Prediction (LCP) AI, a deep learning and radiomics model that analyzes chest CT images to produce a malignancy risk score and is described as the world's only FDA-cleared and UKCA/CE-marked reimbursable radiomics AI for lung cancer diagnosis; Patient Discovery AI, which uses NLP to run overnight searches across radiology reports (reported at 100% sensitivity and 98% specificity); and workflow management tools for triage, tracking, and care coordination. The company has developed what it calls the world's first thorax CT foundation model and offers adjacent modules including LCP Maxscreen (5-year population risk), LungRecur (post-surgical recurrence prediction), and Virtual Nodule Clinic Pro (end-to-end automation).

The company's revenue model rests on three streams: enterprise SaaS subscriptions to hospitals, health systems, and imaging centers; per-use Medicare reimbursement at $650 per LCP analysis; and partnerships with life sciences companies (Bristol Myers Squibb, GE Healthcare, Johnson & Johnson, Concert AI) for clinical development, patient enrollment, and commercial applications. As of mid-2026, Optellum reported deployments at 250+ clinical sites spanning the US, UK, and Australia, with over 3 million cases analyzed. Named enterprise customers include University of Pennsylvania Health System, Vanderbilt University Medical Center, Atrium Health, Penn Medicine, UConn Health, Jupiter Medical Center, Georgia Cancer Center, and NHS trusts in London. The go-to-market combines direct enterprise sales with embedded distribution through partnerships with Intuitive Surgical (robotic bronchoscopy), GE Healthcare (imaging), and life sciences co-development deals.

Short descriptiontext

Optellum develops FDA-cleared AI software for early lung cancer detection and lung nodule risk stratification, serving hospitals, health systems, and life sciences companies across the US, UK, and Australia with a Medicare-reimbursable platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersOxford, United Kingdom
HQ citystring
Oxford
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
lung cancer detection, clinical decision support, medical imaging AI, radiology software platform, lung nodule management
Industry4 codes
PRIMARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLAKANAI
Lung Cancer Screening & Pulmonary Nodule Clinic
SECONDARYHLACABAM
Imaging & Diagnostic Interoperability (DICOM exchange, image sharing, VNA connectivity)
Healthcare & Life Sciences/Digital Health & Health IT/Health Information Exchange (HIE) & Interoperability
SECONDARYHLACALAD
Universal Viewers & Enterprise Imaging Access (Zero-footprint/Diagnostic)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
NAICS code1 code
  • Computer Systems Design and Related Services54151
SIC code1 code
  • Services-Misc Health & Allied Services, Nec8090
Product category
Clinical Decision Support / Medical Imaging AI for Lung Cancer Diagnosis
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Virtual Nodule Clinic Licensing
TypeSubscription Recurring
Description

SaaS-based licensing model for the Virtual Nodule Clinic platform, providing AI-powered lung nodule risk stratification and care coordination tools to healthcare providers. Revenue generated through subscription licensing with healthcare systems and hospitals.

optellum.com
2Medicare Reimbursement (Per Use)
TypeUsage Based
Description

Optellum's LCP AI is reimbursable under Medicare at $650 per use. This creates a per-procedure revenue stream that supplements subscription licensing.

optellum.com
3Life Sciences Partnerships
TypeSubscription Recurring
Description

Partnerships with biopharma companies (Bristol Myers Squibb) and MedTech companies (GE Healthcare, Johnson & Johnson) for clinical development, patient enrollment acceleration, and commercial applications.

optellum.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Infrastructure, Operations
Pricing details2 tiers
1Enterprise hospital/health system licensing
ModelSubscriptionBilling cadenceAnnual
Notes

Quote-based pricing for healthcare systems and hospitals implementing Virtual Nodule Clinic. Includes implementation, training, and ongoing support.

optellum.com
2Medicare per-use reimbursement
ModelUsage-basedBilling cadencePay-as-you-go
Notes

$650 per use under Medicare for LCP AI analysis. This represents a usage-based component that healthcare providers can claim for each patient analysis.

optellum.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 5 records shown
1Virtual Nodule Clinic (VNC)
Description

AI-powered early lung cancer diagnosis solution for discovering, tracking, and assessing risk of malignancy in lung nodule patients. The world's only FDA-cleared and UKCA/CE-marked reimbursable radiomics AI solution for lung cancer diagnosis.

optellum.com
+4 more records
Core offering1 text field

Optellum provides an AI-powered lung precision care platform built around its FDA-cleared Virtual Nodule Clinic (VNC), combining radiomics, deep learning, and NLP to discover lung nodules in radiology reports, predict malignancy risk from chest CT images, and coordinate triage and follow-up workflows. The platform integrates with hospital EHR (Epic, Oracle Cerner) and PACS systems via HL7 and DICOM, and is sold primarily as enterprise SaaS to hospitals, health systems, and imaging centers. A secondary set of offerings targets biopharma and MedTech partners through co-development, patient enrollment, and real-world evidence collaborations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 71% more interventional procedures at hospitals using Virtual Nodule Clinic
+6 more records
Product overview1 text field

Optellum offers a unified lung precision care platform centered on its Virtual Nodule Clinic (VNC), which serves as the core product for early lung cancer diagnosis. The platform is powered by three interconnected AI technologies: Lung Cancer Prediction (LCP) AI (FDA-cleared, reimbursable radiomics solution for malignancy risk scoring), Patient Discovery AI (automated NLP-based nodule finding from radiology reports), and workflow management tools (triage, tracking, and patient dashboards). Additional products include LCP Maxscreen (population health screening), Zero-click LCP (automated radiology workflow augmentation), and Virtual Nodule Clinic Pro (combining core technologies). The company is expanding into a broader LungOS platform with products like LungDetect (European launch) and LungRecur (recurrence prediction). The architecture follows a platform-plus-modules approach where VNC serves as the foundation, with specialized add-on modules targeting specific use cases in screening, population health, and treatment optimization.

Product and service4 records
1Virtual Nodule Clinic (VNC)
CategoryLung cancer diagnostic software platform
Description

AI-powered early lung cancer diagnosis solution for discovering, tracking, and assessing malignancy risk in lung nodule patients, integrating with EHR and PACS systems and combining Optellum's LCP AI, Patient Discovery AI, and triage/management workflows. Sold to hospitals, health systems, and imaging centers as enterprise software.

2Lung Cancer Prediction (LCP) AI
CategoryRadiomics-based clinical decision support AI
Description

The world's only FDA-cleared, UKCA/CE-marked, and reimbursable radiomics AI solution for lung cancer diagnosis, using deep learning and radiomics on chest CT images to produce a malignancy risk score that outperforms standard-of-care models such as Brock and Mayo. Sold to healthcare providers and reimbursable under Medicare at approximately $650 per use.

3Lung Cancer Screening (LCS) Solution
CategoryLung cancer screening program management software
Description

Complete solution for lung cancer screening programs that helps health systems, hospitals, and imaging centers manage screening efficiently and precisely through centralized patient tracking, automated follow-up alerts, and EHR/PACS integration.

4LungOS
CategoryLung health operating system platform
Description

AI-powered lung health platform positioned as the operating system for thoracic care, expanding Optellum's offering beyond lung cancer diagnosis into a broader lung health platform.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-06-10
Description

Regional health system partnership to launch Optellum's Virtual Nodule Clinic AI platform, serving patients across west Georgia and east Alabama. One of the first regional health systems in Georgia to implement FDA-cleared AI technology system-wide.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-06-10
Description

Partner with Tanner Health and Optellum to bring AI lung health solutions to the region.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-03
Description

Collaboration to connect AI-powered lung cancer detection with clinical trial matching for early-stage NSCLC patients. Optellum's FDA-cleared LCP AI identifies high-risk patients, whose data is processed by Massive Bio's platform to match with geographically accessible clinical trials.

Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-02-01
Description

Pilot program location for NHS integration of Optellum's FDA-cleared AI-powered Virtual Nodule Clinic with robotic-assisted bronchoscopy. This is the first NHS integration of AI diagnostic software with robotic-assisted bronchoscopy.

Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-02-01
Description

Planned expansion site for NHS pilot program integrating Optellum's AI platform with robotic-assisted bronchoscopy for lung cancer diagnostics.

Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-02-01
Description

Planned expansion site for NHS pilot program integrating Optellum's AI platform with robotic-assisted bronchoscopy for lung cancer diagnostics.

7Bristol Myers Squibb
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

First-of-its-kind partnership to evaluate real-world impact of AI on patient outcomes. Bristol Myers Squibb is evaluating Optellum's AI platform for lung cancer care optimization.

prnewswire.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Partnership with NHS in the UK to integrate Optellum's AI diagnostic software with robotic-assisted bronchoscopy. Intuitive Surgical provides robotic surgical systems.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-01-01
Description

Collaboration with GE Healthcare for lung cancer diagnosis and treatment. GE Healthcare is a major medical imaging and digital solutions provider.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Collaboration for lung cancer diagnosis and treatment expansion. Johnson & Johnson is a major healthcare conglomerate with pharmaceutical and medical device businesses.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2016-01-01
Description

Optellum is a 2016 spinout from the University of Oxford. Ongoing academic partnership for research collaboration, biomarker development, and clinical validation.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

South Korea-based AI company developing deep-learning solutions for cancer detection, including lung nodule and chest X-ray AI (Lunit INSIGHT CXR/Nodule). Directly competes with Optellum in lung cancer imaging AI and is more broadly scaled with public-market access.

TypeDirect peer
Description

AI radiology company offering FDA-cleared solutions for chest CT and X-ray interpretation, including lung nodule detection and TB screening. Direct competitor to Optellum in AI lung nodule detection with overlapping hospital customer base.

TypeDirect peer
Description

Provides ClearRead CT and ClearRead XR AI tools for lung nodule detection and chest X-ray interpretation, with established US hospital deployments. Directly competes with Optellum's lung nodule AI offering.

TypeDirect peer
Description

Broad radiology AI platform offering FDA-cleared algorithms across multiple anatomies including chest CT, with similar enterprise health-system GTM. While not lung-nodule-only, it directly overlaps Optellum's provider customer base and product category.

TypeDirect peer
Description

Comprehensive radiology AI platform covering chest X-ray and CT findings including lung nodules. Direct competitor to Optellum in AI lung imaging with similar regulatory and enterprise GTM approach.

TypeDirect peer
Description

AI-powered imaging subsidiary of RadNet offering lung and broader radiology AI. Competitor in lung nodule and screening workflows with the backing of one of the largest US imaging network operators.

TypeEmerging player
Description

UK-based radiology AI company with FDA-cleared chest X-ray and CT triage algorithms. Emerging peer with overlapping lung imaging focus and similar UK heritage to Optellum.

TypeEmerging player
Description

AI imaging company focused on brain MRI (icobrain) with FDA clearance and similar enterprise hospital GTM. Adjacent peer with comparable regulatory and reimbursement model applicable to Optellum's lung platform strategy.

TypeBroad incumbent
Description

Major medical imaging OEM offering AI-Rad Companion platform with lung CT analysis capabilities. Broad incumbent that bundles AI features into enterprise imaging equipment contracts, competing with Optellum at the procurement level.

TypeBroad incumbent
Description

Global imaging OEM and partner of Optellum with its own Edison AI platform and lung CT analytics. Serves as both a channel partner and a potential competitive threat as it expands native AI offerings.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration4 records

Each record includes

Title, Type, Description, Source

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Optellum

Clinical Decision Support / Medical Imaging AI for Lung Cancer Diagnosisoptellum.com

Optellum develops FDA-cleared AI software for early lung cancer detection and lung nodule risk stratification, serving hospitals, health systems, and life sciences companies across the US, UK, and Australia with a Medicare-reimbursable platform.

What Optellum does

Optellum is an Oxford-headquartered medtech company, founded in 2016 as a spinout from the University of Oxford, that develops AI-powered software for early lung cancer detection and lung nodule management. Its core platform, the Virtual Nodule Clinic (VNC), combines three proprietary technologies: Lung Cancer Prediction (LCP) AI, a deep learning and radiomics model that analyzes chest CT images to produce a malignancy risk score and is described as the world's only FDA-cleared and UKCA/CE-marked reimbursable radiomics AI for lung cancer diagnosis; Patient Discovery AI, which uses NLP to run overnight searches across radiology reports (reported at 100% sensitivity and 98% specificity); and workflow management tools for triage, tracking, and care coordination. The company has developed what it calls the world's first thorax CT foundation model and offers adjacent modules including LCP Maxscreen (5-year population risk), LungRecur (post-surgical recurrence prediction), and Virtual Nodule Clinic Pro (end-to-end automation).

The company's revenue model rests on three streams: enterprise SaaS subscriptions to hospitals, health systems, and imaging centers; per-use Medicare reimbursement at $650 per LCP analysis; and partnerships with life sciences companies (Bristol Myers Squibb, GE Healthcare, Johnson & Johnson, Concert AI) for clinical development, patient enrollment, and commercial applications. As of mid-2026, Optellum reported deployments at 250+ clinical sites spanning the US, UK, and Australia, with over 3 million cases analyzed. Named enterprise customers include University of Pennsylvania Health System, Vanderbilt University Medical Center, Atrium Health, Penn Medicine, UConn Health, Jupiter Medical Center, Georgia Cancer Center, and NHS trusts in London. The go-to-market combines direct enterprise sales with embedded distribution through partnerships with Intuitive Surgical (robotic bronchoscopy), GE Healthcare (imaging), and life sciences co-development deals.

Optellum firmographics

Firmographics
Name
Optellum
Legal name
Optellum Ltd.
Website
https://optellum.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
51–100 employees
Short description
Optellum develops FDA-cleared AI software for early lung cancer detection and lung nodule risk stratification, serving hospitals, health systems, and life sciences companies across the US, UK, and Australia with a Medicare-reimbursable platform.
Ownership category
akta.pro rank

Optellum industry classification

Industry
Product category
Clinical Decision Support / Medical Imaging AI for Lung Cancer Diagnosis
NAICS
Computer Systems Design and Related Services (54151)
SIC
Services-Misc Health & Allied Services, Nec (8090)
akta.pro industry
PRIMARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLAKANAI
Lung Cancer Screening & Pulmonary Nodule Clinic
SECONDARYHLACABAM
Imaging & Diagnostic Interoperability (DICOM exchange, image sharing, VNA connectivity)
Healthcare & Life Sciences/Digital Health & Health IT/Health Information Exchange (HIE) & Interoperability
SECONDARYHLACALAD
Universal Viewers & Enterprise Imaging Access (Zero-footprint/Diagnostic)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT

Keywords

  • Lung cancer detection
  • Clinical decision support
  • Medical imaging AI
  • Radiology software platform
  • Lung nodule management

Where Optellum is headquartered

Location

Headquarters

HQ city
Oxford
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Optellum business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Infrastructure, Operations

Revenue model

  1. Virtual Nodule Clinic Licensing: SaaS-based licensing model for the Virtual Nodule Clinic platform, providing AI-powered lung nodule risk stratification and care coordination tools to healthcare providers. Revenue generated through subscription licensing with healthcare systems and hospitals.
  2. Medicare Reimbursement (Per Use): Optellum's LCP AI is reimbursable under Medicare at $650 per use. This creates a per-procedure revenue stream that supplements subscription licensing.
  3. Life Sciences Partnerships: Partnerships with biopharma companies (Bristol Myers Squibb) and MedTech companies (GE Healthcare, Johnson & Johnson) for clinical development, patient enrollment acceleration, and commercial applications.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise hospital/health system licensing
Usage-basedPay-as-you-goMedicare per-use reimbursement

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Optellum product offering

Product offering

Core offering

Optellum provides an AI-powered lung precision care platform built around its FDA-cleared Virtual Nodule Clinic (VNC), combining radiomics, deep learning, and NLP to discover lung nodules in radiology reports, predict malignancy risk from chest CT images, and coordinate triage and follow-up workflows. The platform integrates with hospital EHR (Epic, Oracle Cerner) and PACS systems via HL7 and DICOM, and is sold primarily as enterprise SaaS to hospitals, health systems, and imaging centers. A secondary set of offerings targets biopharma and MedTech partners through co-development, patient enrollment, and real-world evidence collaborations.

Product overview

Optellum offers a unified lung precision care platform centered on its Virtual Nodule Clinic (VNC), which serves as the core product for early lung cancer diagnosis. The platform is powered by three interconnected AI technologies: Lung Cancer Prediction (LCP) AI (FDA-cleared, reimbursable radiomics solution for malignancy risk scoring), Patient Discovery AI (automated NLP-based nodule finding from radiology reports), and workflow management tools (triage, tracking, and patient dashboards). Additional products include LCP Maxscreen (population health screening), Zero-click LCP (automated radiology workflow augmentation), and Virtual Nodule Clinic Pro (combining core technologies). The company is expanding into a broader LungOS platform with products like LungDetect (European launch) and LungRecur (recurrence prediction). The architecture follows a platform-plus-modules approach where VNC serves as the foundation, with specialized add-on modules targeting specific use cases in screening, population health, and treatment optimization.

Differentiator

Problem solved

Functional benefit

Brands

  • Virtual Nodule Clinic (VNC): AI-powered early lung cancer diagnosis solution for discovering, tracking, and assessing risk of malignancy in lung nodule patients. The world's only FDA-cleared and UKCA/CE-marked reimbursable radiomics AI solution for lung cancer diagnosis.
  • Lung Cancer Prediction (LCP) AI
  • Patient Discovery AI
  • LungOS
  • Lung Cancer Screening (LCS)

Products and services

  • Virtual Nodule Clinic (VNC) AI-powered early lung cancer diagnosis solution for discovering, tracking, and assessing malignancy risk in lung nodule patients, integrating with EHR and PACS systems and combining Optellum's LCP AI, Patient Discovery AI, and triage/management workflows. Sold to hospitals, health systems, and imaging centers as enterprise software.
  • Lung Cancer Prediction (LCP) AI The world's only FDA-cleared, UKCA/CE-marked, and reimbursable radiomics AI solution for lung cancer diagnosis, using deep learning and radiomics on chest CT images to produce a malignancy risk score that outperforms standard-of-care models such as Brock and Mayo. Sold to healthcare providers and reimbursable under Medicare at approximately $650 per use.
  • Lung Cancer Screening (LCS) Solution Complete solution for lung cancer screening programs that helps health systems, hospitals, and imaging centers manage screening efficiently and precisely through centralized patient tracking, automated follow-up alerts, and EHR/PACS integration.
  • LungOS AI-powered lung health platform positioned as the operating system for thoracic care, expanding Optellum's offering beyond lung cancer diagnosis into a broader lung health platform.

Quantifiable outcome

  • 71% more interventional procedures at hospitals using Virtual Nodule Clinic
  • +6 more outcomes

Companies that use Optellum

Customer profile

Named customers10 records

Segments4 records

Ideal customer profiles3 records

Optellum technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability8 records

Feature7 records

Optellum partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core and minor.

  • Tanner HealthcoreImplementation/ SI/ Consulting Partner · 10 June 2026Regional health system partnership to launch Optellum's Virtual Nodule Clinic AI platform, serving patients across west Georgia and east Alabama. One of the first regional health systems in Georgia to implement FDA-cleared AI technology system-wide.
  • Healthliant VenturesminorGTM or Marketing Partner · 10 June 2026Partner with Tanner Health and Optellum to bring AI lung health solutions to the region.
  • Massive BiocoreStrategic or Co-development Partner · 3 June 2026Collaboration to connect AI-powered lung cancer detection with clinical trial matching for early-stage NSCLC patients. Optellum's FDA-cleared LCP AI identifies high-risk patients, whose data is processed by Massive Bio's platform to match with geographically accessible clinical trials.
  • Guy's and St Thomas' NHS Foundation TrustcoreImplementation/ SI/ Consulting Partner · 1 February 2026Pilot program location for NHS integration of Optellum's FDA-cleared AI-powered Virtual Nodule Clinic with robotic-assisted bronchoscopy. This is the first NHS integration of AI diagnostic software with robotic-assisted bronchoscopy.
  • King's College Hospital NHS Foundation TrustcoreImplementation/ SI/ Consulting Partner · 1 February 2026Planned expansion site for NHS pilot program integrating Optellum's AI platform with robotic-assisted bronchoscopy for lung cancer diagnostics.
  • Lewisham and Greenwich NHS TrustcoreImplementation/ SI/ Consulting Partner · 1 February 2026Planned expansion site for NHS pilot program integrating Optellum's AI platform with robotic-assisted bronchoscopy for lung cancer diagnostics.
  • Bristol Myers SquibbcoreStrategic or Co-development Partner · 1 January 2024First-of-its-kind partnership to evaluate real-world impact of AI on patient outcomes. Bristol Myers Squibb is evaluating Optellum's AI platform for lung cancer care optimization.
  • Intuitive SurgicalcoreStrategic or Co-development Partner · 1 January 2024Partnership with NHS in the UK to integrate Optellum's AI diagnostic software with robotic-assisted bronchoscopy. Intuitive Surgical provides robotic surgical systems.
  • GE HealthcarecoreTechnology or Integration · 1 January 2022Collaboration with GE Healthcare for lung cancer diagnosis and treatment. GE Healthcare is a major medical imaging and digital solutions provider.
  • Johnson & JohnsoncoreStrategic or Co-development Partner · 1 January 2022Collaboration for lung cancer diagnosis and treatment expansion. Johnson & Johnson is a major healthcare conglomerate with pharmaceutical and medical device businesses.
  • University of OxfordcoreStrategic or Co-development Partner · 1 January 2016Optellum is a 2016 spinout from the University of Oxford. Ongoing academic partnership for research collaboration, biomarker development, and clinical validation.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Optellum competitors and assessment

Company assessment

Direct peers

  • Lunit: South Korea-based AI company developing deep-learning solutions for cancer detection, including lung nodule and chest X-ray AI (Lunit INSIGHT CXR/Nodule). Directly competes with Optellum in lung cancer imaging AI and is more broadly scaled with public-market access.
  • Qure.ai: AI radiology company offering FDA-cleared solutions for chest CT and X-ray interpretation, including lung nodule detection and TB screening. Direct competitor to Optellum in AI lung nodule detection with overlapping hospital customer base.
  • Riverain Technologies: Provides ClearRead CT and ClearRead XR AI tools for lung nodule detection and chest X-ray interpretation, with established US hospital deployments. Directly competes with Optellum's lung nodule AI offering.
  • Aidoc: Broad radiology AI platform offering FDA-cleared algorithms across multiple anatomies including chest CT, with similar enterprise health-system GTM. While not lung-nodule-only, it directly overlaps Optellum's provider customer base and product category.
  • Annalise.ai: Comprehensive radiology AI platform covering chest X-ray and CT findings including lung nodules. Direct competitor to Optellum in AI lung imaging with similar regulatory and enterprise GTM approach.
  • DeepHealth (RadNet subsidiary): AI-powered imaging subsidiary of RadNet offering lung and broader radiology AI. Competitor in lung nodule and screening workflows with the backing of one of the largest US imaging network operators.

Emerging players

  • Behold.ai: UK-based radiology AI company with FDA-cleared chest X-ray and CT triage algorithms. Emerging peer with overlapping lung imaging focus and similar UK heritage to Optellum.
  • icometrix: AI imaging company focused on brain MRI (icobrain) with FDA clearance and similar enterprise hospital GTM. Adjacent peer with comparable regulatory and reimbursement model applicable to Optellum's lung platform strategy.

Broad incumbents

  • Siemens Healthineers (AI-Rad Companion): Major medical imaging OEM offering AI-Rad Companion platform with lung CT analysis capabilities. Broad incumbent that bundles AI features into enterprise imaging equipment contracts, competing with Optellum at the procurement level.
  • GE Healthcare (Edison Platform): Global imaging OEM and partner of Optellum with its own Edison AI platform and lung CT analytics. Serves as both a channel partner and a potential competitive threat as it expands native AI offerings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Optellum social profiles

Digital presence

Optellum compliance and trust

Trust signal

Compliance7 records

Optellum financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Optellum leadership team

Management profile

Number of profiles

Profiles1 record

Optellum subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Optellum funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Optellum M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Optellum

What does Optellum do?

Optellum provides an AI-powered lung precision care platform built around its FDA-cleared Virtual Nodule Clinic (VNC), combining radiomics, deep learning, and NLP to discover lung nodules in radiology reports, predict malignancy risk from chest CT images, and coordinate triage and follow-up workflows. The platform integrates with hospital EHR (Epic, Oracle Cerner) and PACS systems via HL7 and DICOM, and is sold primarily as enterprise SaaS to hospitals, health systems, and imaging centers. A secondary set of offerings targets biopharma and MedTech partners through co-development, patient enrollment, and real-world evidence collaborations.

Is Optellum a public or private company?

Optellum is a private company. It is classified as venture growth investor backed and is currently operating.

When was Optellum founded?

Optellum was founded in 2016. It employs 51 to 100 people.

Where is Optellum based?

Optellum is headquartered in Oxford, United Kingdom, in the Europe region.

How does Optellum make money?

Three revenue lines are on record. Virtual Nodule Clinic Licensing is the primary driver. The others are medicare Reimbursement (Per Use) and life Sciences Partnerships.

Who are Optellum's main competitors?

Direct peers on record are Lunit, Qure.ai, Riverain Technologies, Aidoc, Annalise.ai and DeepHealth (RadNet subsidiary). Emerging players are Behold.ai and icometrix. Broad incumbents are Siemens Healthineers (AI-Rad Companion) and GE Healthcare (Edison Platform).

Does Optellum have an API?

No public API is recorded for Optellum.

What industry is Optellum in?

Optellum's product category is Clinical Decision Support / Medical Imaging AI for Lung Cancer Diagnosis. Its primary akta.pro industry code is HLACALAG, AI Orchestration & Imaging Analytics Platforms (Model Management/Triage), with a secondary code of HLAKANAI, Lung Cancer Screening & Pulmonary Nodule Clinic. Its NAICS code is 54151 and its SIC code is 8090.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Imaging Technology NewsOptellum’s Virtual Nodule Clinic Now Available on RapidAI’s Enterprise PlatformOptellum integrated its Virtual Nodule Clinic with RapidAI's Enterprise Platform, expanding lung nodule AI access. The FDA-cleared, Medicare-reimbursed solution has analyzed over 3 million cases. Integration aims to accelerate deployment across health systems using RapidAI.AuntMinnieSimonMed, Optellum partner on AI lung nodule risk assessmentSimonMed is integrating Optellum's FDA-cleared lung cancer prediction AI into its lung nodule clinical workflow, routing eligible nodules from chest CT scans into Optellum's Lung Cancer Prediction AI for scoring. Each score is reviewed by a board-certified SimonMed radiologist before inclusion in the final report. The workflow will cover more than 175 outpatient imaging centers across 10 states.Medical Device NetworkOptellum and Coreline Soft plan AI integration for lung nodule careOptellum and Coreline Soft have announced a partnership to integrate Coreline Soft's FDA-cleared AVIEW Lung Nodule CAD detection software into Optellum's LungOS platform. The collaboration aims to combine detection capabilities with risk assessment and care management solutions to streamline the clinical workflow for lung nodule patients across international markets.YahooCoreline Soft and Optellum announce intent to collaborate to advance AI across the lung cancer pathwayOptellum and Coreline Soft announced an intent to collaborate, making Coreline Soft's FDA-cleared AVIEW Lung Nodule CAD software available through Optellum's LungOS platform. This partnership aims to integrate detection capabilities with risk assessment workflows to support earlier diagnosis and management of lung nodules in the US. The move addresses a significant healthcare challenge where early detection substantially improves five-year survival rates for lung cancer.PR Newswire APACCoreline Soft and Optellum announce intent to collaborate to advance AI across the lung cancer pathwayCoreline Soft and Optellum announced an intent to collaborate, integrating Coreline Soft's FDA-cleared AVIEW Lung Nodule CAD software into Optellum's LungOS platform. This partnership aims to create a more integrated workflow for lung nodule detection, risk assessment, and care management to support earlier diagnosis and treatment of lung cancer.ThemalaysianreserveCoreline Soft and Optellum announce intent to collaborate to advance AI across the lung cancer pathwayOptellum and Coreline Soft announced an intent to collaborate, making Coreline Soft’s FDA-cleared AVIEW Lung Nodule CAD software available through Optellum’s LungOS platform. This partnership aims to integrate detection capabilities with risk assessment and care management workflows to improve the lung cancer diagnostic pathway. The collaboration addresses the challenge of managing incidental lung nodules found in millions of annual chest CT examinations.PR NewswireCoreline Soft and Optellum announce intent to collaborate to advance AI across the lung cancer pathwayOptellum and Coreline Soft announced a collaboration to integrate Coreline Soft's FDA-cleared lung nodule detection software into Optellum's LungOS platform. The partnership aims to connect detection with risk assessment and care management, supporting earlier lung cancer diagnosis. The companies expect to connect their expertise in chest CT-based detection with Optellum's risk assessment workflow.Clinical Trials ArenaMassive Bio and FOMAT collaborate for oncology clinical trialsMassive Bio and FOMAT launched a pilot to use AI prescreening for oncology clinical trials across FOMAT's US physician network. The AI platform has facilitated over 19,000 trial matches and is listed in the CMS Medicare App Library, potentially connecting with over 68 million Medicare beneficiaries. The pilot's outcomes will determine further expansion.Business Wire BlogTanner Health and Healthliant Ventures Partner With Optellum to Bring AI for Lung Health to the RegionTanner Health and Healthliant Ventures announced a partnership with Optellum to launch the company's Virtual Nodule Clinic AI platform, designed to assist clinicians in identifying and risk-assessing patients with potentially cancerous lung nodules. The technology uses advanced imaging analytics and machine learning to assess lung nodule malignancy risk, enabling earlier detection while reducing unnecessary invasive procedures. The deployment marks one of the first regional health systems in Georgia to implement the FDA-cleared AI technology system-wide, serving patients across west Georgia and east Alabama.PR NewswireOptellum Celebrates Accelerating Impact in Lung Cancer Care; Now at Over 250 Sites and GrowingOptellum, an AI-enabled lung cancer diagnostics company headquartered in Oxford, UK, announced it has surpassed 250 clinical sites and analyzed more than 3 million cases as of June 4, 2026, helping approximately one patient every 14 seconds. The milestone reflects commercial momentum supported by first-of-its-kind partnerships with Bristol Myers Squibb in the US and with the NHS and Intuitive Surgical in the UK, along with deployments at major health systems including University of Pennsylvania Health System, Vanderbilt University Medical Center, and Oxford University Hospitals. The company is expanding its LungOS AI-powered lung health platform and preparing for the European launch of LungDetect, positioning itself as the operating system for thoracic care.